Pulmonary Embolism – Thrombolex THRO-CLIN-2024-01

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

This study is being conducted to demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).

Inclusion Criteria

• • Willing and able to provide informed consent;
  • PE symptom duration ≤ 15 days;
  • Filling defect in at least one major lobar pulmonary artery as determined by CTA;
  • Patient is diagnosed with intermediate risk PE;
  • RV/LV diameter ratio ≥ 0.9 by CTA, as determined by investigative site;
  • Willing and able to comply with all study procedures and 7-day and 30-day telephone follow-up visit.
  • Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.